Radiofrequency for hepatocellular carcinoma larger than 3 cm: potential for applications in daily practice [0.03%]
大于3cm的肝细胞癌射频治疗：在日常实践中的应用潜力
Ji Hoon Kim,Pil Soo Sung
Ji Hoon Kim
Intermediate-stage hepatocellular carcinoma: refining substaging or shifting paradigm? [0.03%]
中间阶段肝细胞癌：细化分期还是转换理念？
Bernardo Stefanini,Luca Ielasi,Dante Pio Pallotta et al.
Bernardo Stefanini et al.
This review explores the evolution of cancer staging, focusing on intermediate hepatocellular carcinoma (HCC), and the challenges faced by physicians. The Barcelona Clinic Liver Cancer (BCLC) staging system, introduced in 1999, was designed...
Liver resection in selective hepatocellular carcinoma with Vp3 or Vp4 portal vein tumor thrombosis improves prognosis [0.03%]
选择性肝细胞癌伴门静脉三级或四级瘤栓的肝切除术可改善预后
Manuel Lim,Jongman Kim,Jinsoo Rhu et al.
Manuel Lim et al.
Background/aim: Hepatocellular carcinoma (HCC) tumor thrombi located in the first branch of the portal vein (Vp3) or in the main portal trunk (Vp4) are associated with poor prognosis. This study aimed to investigate the c...
Additional nodules detected using EOB-MRI in patients with resectable single hepatocellular carcinoma: an implication for active treatment strategy [0.03%]
EOB-MRI在可切除的单发肝细胞癌患者中检测到额外结节：对积极治疗策略的影响
Na Reum Kim,Seoung Yoon Rho,Jonathan Navarro et al.
Na Reum Kim et al.
Background/aim: Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (EOBMRI) further enhances the identification of additional hepatic nodules compared with computed tomography ...
Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis [0.03%]
阿特珠单抗联合贝伐珠单抗与乐伐替尼在治疗合并门静脉癌栓的肝细胞癌中的比较研究
Jeayeon Park,Yun Bin Lee,Yunmi Ko et al.
Jeayeon Park et al.
Background/aim: Atezolizumab plus bevacizumab and lenvatinib are currently available as first-line therapy for the treatment of unresectable hepatocellular carcinoma (HCC). However, comparative efficacy studies are still ...
Reply to the Letter regarding "Treatment options for solitary hepatocellular carcinoma ≤5 cm: surgery vs. ablation: a multicenter retrospective study" [0.03%]
《≤5cm的孤立性肝细胞癌的治疗选择：手术vs消融--一项多中心回顾研究》的来信回复
Kazuhiro Nouso,Kazuya Kariyama
Kazuhiro Nouso
Intrahepatic cholangiocarcinoma: histological diversity and the role of the pathologist [0.03%]
肝内胆管细胞癌：组织学多样性与病理学家的作用
Mina Komuta
Mina Komuta
Intrahepatic cholangiocarcinoma (iCCA) is one of the primary liver cancers and presents with tumor heterogeneity. About 50% of iCCAs comprise actionable mutations, which completely change patient management. In addition, the precise diagnos...
Young-Gi Song,Jeong-Ju Yoo,Sang Gyune Kim et al.
Young-Gi Song et al.
Immune checkpoint inhibitors (ICIs) are highly effective in cancer treatment. However, the risks associated with the treatment must be carefully balanced against the therapeutic benefits. Immune-related adverse events (irAEs) are generally ...
Metastatic papillary renal cell carcinoma with portal vein tumor thrombosis confirmed on blind liver biopsy [0.03%]
经盲肝活检证实的合并门静脉癌栓的转移性乳头状肾细胞癌
Hun Kim,Tae Hoon Roh,Jun Seop Lee et al.
Hun Kim et al.
Portal vein tumor thrombosis (PVTT) is an uncommon condition in which tumor cells expand into the vessels, causing blood clot formation in the portal vein. PVTT is mainly associated with hepatocellular carcinoma, leading to an unfavorable p...